Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval

Challenges in time to event type 1 diabetes (T1D) prevention trial design can yield negative results even for treatments that may actually improve disease pathology. We evaluated whether a binary metabolic end point for 12-month change from baseline to 1 year postrandomization could be useful in T1D prevention trials. This approach detected treatment effects at least as well as standard primary end points with shorter follow-up. Fixed interval metabolic end points should be used in combination with traditional T1D end points to better understand treatment effects of preventive agents.

Authors

Institutions

Publication Details

Journal
Diabetes
Published
2025-08-28
DOI
https://doi.org/10.2337/db25-0310
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval

William E. Russell, Colin Mark Dayan, Jay S. Skyler, Kevan C. Herold et al.
Diabetes
Diabetes Management and Research
article

Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval

William E. Russell, Colin Mark Dayan, Jay S. Skyler, Kevan C. Herold, MARIA JOSE REDONDO, Emily K. Sims, Heba M. Ismail, Jay M. Sosenko, Peter Nicholas Taylor, Brandon M. Nathan, Alice L. J. Carr, Alfonso Galderisi, David Cuthbertson, Laura M. Jacobsen
article en

Abstract

Challenges in time to event type 1 diabetes (T1D) prevention trial design can yield negative results even for treatments that may actually improve disease pathology. We evaluated whether a binary metabolic end point for 12-month change from baseline to 1 year postrandomization could be useful in T1D prevention trials. This approach detected treatment effects at least as well as standard primary end points with shorter follow-up. Fixed interval metabolic end points should be used in combination with traditional T1D end points to better understand treatment effects of preventive agents.

DiabetesVol. 74(11)
University of Minnesota (US), University of Miami (US), University of Alberta (CA), Vanderbilt University (US), University of South Florida (US), Yale University (US), University of Florida (US), MNGI Digestive Health (US), Texas Children's Hospital (US), Indiana University – Purdue University Indianapolis (US), Cardiff University (GB), Cardiff Metropolitan University (GB), Florida College (US), University of Wales (GB)
Doris Duke Charitable Foundation, John Templeton Foundation, National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources
Openalex Percentile: Top 69%
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.